Celgene to buy Impact Biomedicines for up to $7 billion: Reuters

U.S. biotech pharmaceutical firm Celgene Corp (CELG.O) said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.